Literature DB >> 18377780

When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.

John F Oram1, Jay W Heinecke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18377780     DOI： 10.1007/s11883-007-0055-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  11 in total

Review 1.  Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

Authors:  Baohai Shao; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  Curr Opin Cardiol       Date:  2006-07       Impact factor: 2.161

Review 2.  Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.

Authors:  Danielle Duffy; Daniel J Rader
Journal:  Circulation       Date:  2006-02-28       Impact factor: 29.690

3.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

Review 5.  ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease.

Authors:  John F Oram; Jay W Heinecke
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

6.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.

Authors:  H Okamoto; F Yonemori; K Wakitani; T Minowa; K Maeda; H Shinkai
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

Review 8.  Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.

Authors:  Philip J Barter; H Bryan Brewer; M John Chapman; Charles H Hennekens; Daniel J Rader; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

9.  Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Authors:  Laurent Yvan-Charvet; Fumihiko Matsuura; Nan Wang; Mark J Bamberger; Tu Nguyen; Franz Rinninger; Xian-Cheng Jiang; Charles L Shear; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-22       Impact factor: 8.311

10.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Authors:  Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.